CVS Health (CVS) earnings Q2 2024

CVS Health (CVS) earnings Q2 2024

The CVS pharmacy logo is displayed on a sign above a CVS Health Corp. store in Las Vegas, Nevada on Feb. 7, 2024. Patrick T. Fallon | AFP | Getty Images CVS Health on Wednesday reported second-quarter earnings that topped expectations, but slashed its full-year profit outlook, citing higher medical costs that have been squeezing … Read more

Novo Nordisk Q2 2024 results

Novo Nordisk Q2 2024 results

Novo Nordisk Wegovy manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 8, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images) Jakub Porzycki | Nurphoto | Getty Images Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating … Read more

Drugmakers on new negotiated prices with Medicare

Drugmakers on new negotiated prices with Medicare

President Joe Biden speaks during an event at the National Institutes of Health in Bethesda, Maryland, Dec. 14, 2023. Chris Kleponis | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The first round of Medicare drug price negotiations has come … Read more

Eli Lilly Zepbound, Mounjaro available after shortages, FDA says

Eli Lilly Zepbound, Mounjaro available after shortages, FDA says

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration’s drug … Read more

Biogen (BIIB) earnings Q2 2024

Biogen (BIIB) earnings Q2 2024

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and … Read more

Eli Lilly weight loss drug Zepbound cuts heart failure risks in study

Eli Lilly weight loss drug Zepbound cuts heart failure risks in study

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.  Shelby Knowles | Bloomberg | Getty Images Eli Lilly‘s weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company … Read more

Epic Systems will support the government’s TEFCA program for health records

Epic Systems will support the government’s TEFCA program for health records

The eponymous sign outside Epic headquarters in Verona, Wisconsin. Source: Yiem via Wikipedia CC It’s about to get a lot easier for patients in the U.S. to access their own medical records.  Health-care software vendor Epic Systems on Thursday announced that individuals will be able to securely release their health data to different apps they … Read more

Moderna (MRNA) earnings Q2 2024

Moderna (MRNA) earnings Q2 2024

Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025.  The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 … Read more

GEHC gives reasons to look beyond temporary China woes and shares reverse higher

GEHC gives reasons to look beyond temporary China woes and shares reverse higher

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over … Read more

23andMe CEO Anne Wojcicki files proposal to take company private

23andMe CEO Anne Wojcicki files proposal to take company private

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024. Justin Sullivan | Getty Images Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1. Wojcicki said she was prepared to acquire all … Read more